Russell K. Pachynski

Also affiliated with Alvin J. Siteman Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Papers

Driven by 19 papers — median percentile 0. Top paper: “Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial”.

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Cancer Cell(2020)10.1016/j.ccell.2020.08.007

N/A

4.8DataRank · unranked

398 citations

Russell K. Pachynski, Vivek Narayan, Aude Fléchon, Gwénaëlle Gravis, Matthew D. Galsky +10 more

Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness

Cancer Cell(2022)10.1016/j.ccell.2022.12.001

N/A

3.6DataRank · unranked

216 citations

T. Mamie Lih, Saravana M. Dhanasekaran, Rahul Mannan, Lijun Chen, Marcin Cieślik +95 more

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

Frontiers in Oncology(2022)10.3389/fonc.2022.818679

N/A

0.830DataRank · unranked

20 citations

Marcus O. Butler, Russell K. Pachynski, Ryan J. Sullivan, Partow Kebriaei, Sarah Boross-Harmer +20 more

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005813

N/A

0.810DataRank · unranked

25 citations

Jean‐Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K. Pachynski +14 more

A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00798-z

N/A

0.345DataRank · unranked

9 citations

Russell K. Pachynski, Samuel R. Denmeade, Rahul Aggarwal, Jiehui Deng, Victor Adorno Febles +27 more

IMC-Denoise: a content aware denoising pipeline to enhance Imaging Mass Cytometry

Nature Communications(2023)10.1038/s41467-023-37123-6

N/A

0DataRank · unranked

61 citations

Karolyn A. Oetjen, Diane E. Bender, Marianna B. Ruzinova, Daniel A.C. Fisher, Kevin G. Shim +6 more

Chemerin triggers migration of a CD8 T cell subset with natural killer cell functions

Molecular Therapy(2023)10.1016/j.ymthe.2023.08.015

N/A

0DataRank · unranked

15 citations

Melissa LaJevic, Noelle Huskey-Mullin, Rachel Roach, Kevin Brulois, Ying Huang +7 more

PACT: a pipeline for analysis of circulating tumor DNA

Bioinformatics(2023)10.1093/bioinformatics/btad489

N/A

0DataRank · unranked

8 citations

Ha X. Dang, Pradeep S. Chauhan, Wenjia Feng, Alex Shiang, Peter K. Harris +4 more

Preservation of Proteins in Human Plasma through Metal–Organic Framework Encapsulation

ACS Applied Materials & Interfaces(2023)10.1021/acsami.2c21192

N/A

0DataRank · unranked

7 citations

Jeremiah J. Morrissey, Prashant Gupta, Pradeep S. Chauhan, Russell K. Pachynski, Peter K. Harris +3 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in AR -altered lethal prostate cancer

medRxiv(2023)10.1101/2023.12.01.23299215

N/A

0DataRank · unranked

1 citations

Irfan Alahi, Savar Sinha, Alexander L. Shiang, Ryan Mueller, Jace Webster +18 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0400

N/A

0DataRank · unranked

34 citations

Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng +17 more

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1728

N/A

0DataRank · unranked

7 citations

Gurkamal Chatta, Rohit K. Jain, Helen Moon, Scott E. Delacroix, Alana Fang +10 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002903

N/A

0DataRank · unranked

67 citations

Chihiro Morishima, Russell Z. Szmulewitz, Lauren C. Harshman, Leonard J. Appleman, Paul Monk +18 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256

N/A

0DataRank · unranked

98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance

Nature Communications(2022)10.1038/s41467-022-34724-5

N/A

0DataRank · unranked

58 citations

Surbhi Chouhan, Kiran Mahajan, Arun Renganathan, Cody Weimholt, Shambhavi Bhagwat +10 more

Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101199

N/A

0DataRank · unranked

71 citations

Elliot Bradshaw, Carl J. DeSelm, Russell K. Pachynski, Kiran Mahajan, Nupam P. Mahajan +1 more

Russell K. Pachynski

Indexed papers

Top data-sharing exemplar

Papers